What Animal Models Have Taught Us About the Safety and Efficacy of Bisphosphonates in Chronic Kidney Disease

Matthew R. Allen, Mohammad W. Aref

Research output: Contribution to journalReview article

3 Scopus citations


Purpose of Review: Bisphosphonates (BPs) have long been the gold-standard anti-remodeling treatment for numerous metabolic bone diseases. Since these drugs are excreted unmetabolized through the kidney, they are not recommended for individuals with compromised kidney function due to concerns of kidney and bone toxicity. The goal of this paper is to summarize the preclinical BP work in models of kidney disease with particular focus on the bone, kidney, and vasculature. Recent Findings: Summative data exists showing positive effects on bone and vascular calcifications with minimal evidence for bone or kidney toxicity in animal models. Summary: Preclinical data suggest it may be worthwhile to take a step back and reconsider the use of bisphosphonates to lessen skeletal/vascular complications associated with compromised kidney function.

Original languageEnglish (US)
Pages (from-to)171-177
Number of pages7
JournalCurrent osteoporosis reports
Issue number3
StatePublished - Jun 1 2017



  • Anti-resorptive agents
  • Bone mechanics
  • Bone remodeling
  • CKD
  • Renal osteodystrophy
  • Vascular calcification

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism

Cite this